Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines

Tony T. Wu(Kaohsiung Veterans General Hospital), Leland W.K. Chung(VA Palo Alto Health Care System), Quanjun Cui(University of Virginia), Cheryl Murphy(South African Medical Research Council), Robert A. Sikes(University of Virginia), Hua Yang(Qingdao University), Gary Balian(University of Virginia), Haiyen E. Zhau(Cedars-Sinai Medical Center), Chinghai Kao(University of Virginia), George N. Thalmann(University Hospital of Bern)
International Journal of Cancer
September 11, 1998
10.1002/(sici)1097-0215(19980911)77:6<887::aid-ijc15>3.0.co;2-z
Cited by 291

Related Papers

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|798
Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.
|PubMed|1994|739
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656